CAMBRIDGE, Mass.–(BUSINESS WIRE)–Semma Therapeutics, Inc., a biotechnology company pioneering the
curative use of stem cells in regenerative medicine, today announced the
journal Nature published data demonstrating improvements in the
production of beta cells (cells that produce insulin) from stem cells.
Led by Harvard University researchers in collaboration with scientists
from Semma, the study characterized the types of cells produced by the
applicable cell differentiation methods, and demonstrated biological and
physical separation methods to increase the purity of beta cells in a
sample of converted stem cells from 30 to 80 percent.
“The implications of these findings could be tremendously important in
developing effective therapies for the more than 1.25 million people
living with Type 1 diabetes in the U.S.,” said Bastiano Sanna, Ph.D.,
Chief Executive Officer of Semma Therapeutics. “We are immensely
grateful to our collaborators at Harvard University, including Prof.
Doug Melton, whose lab showed for the first time in 2014 that stem cells
could be converted to functional beta cells, and who led the research
presented in this important manuscript. These findings provide a solid
foundation to continue to advance Semma’s mission to develop and provide
best-in-class islet cell therapies for patients.”
Published results summarize the single-cell sequencing and molecular
biology used to identify genes expressed by each cell and the
classification of those cells based on expression patterns. The paper
also details the discovery of a protein expressed uniquely by beta
cells, which was used to “fish” beta cells from the mixture, as well as
a physical enrichment method developed by Semma scientists, which
together were able to improve the purity of beta cells by more than
two-fold.
The manuscript, titled “Charting cellular identity during human in vitro
β-cell differentiation,” may be found here.
A press release issued by Harvard University describes the scientific
findings in brief.
About Semma Therapeutics
Semma Therapeutics is pioneering
the new treatment paradigm of using cells as medicine. Semma’s new class
of regenerative medicine therapies couples its breakthrough stem cell
technologies with proprietary delivery systems designed to protect cells
from the immune system. Ongoing research at Semma Therapeutics is
focused on combining these highly-differentiated active cells with a
state-of-the-art device to provide a functional cure for patients with
diabetes. Semma Therapeutics is working to bring new therapeutic options
to the clinic and improve the lives of patients. The company is
headquartered in Cambridge, MA, with operations in Providence, RI. For
more information, visit www.semma-tx.com.
Contacts
Elliot Fox, W2O Group
+1.212.257.6724
efox@w2ogroup.com